Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

PHASE3CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

July 30, 2024

Study Completion Date

August 27, 2024

Conditions
Nasal Polyps
Interventions
BIOLOGICAL

Depemokimab (GSK3511294)

Depemokimab (GSK3511294) will be administered using a pre- filled syringe.

DRUG

Placebo

Placebo will be administered as normal saline using a pre-filled syringe.

Trial Locations (105)

1023

GSK Investigational Site, Buenos Aires

1900

GSK Investigational Site, La Plata

5500

GSK Investigational Site, Mendoza

7600

GSK Investigational Site, Mar del Plata

9000

GSK Investigational Site, Ghent

11021

GSK Investigational Site, Great Neck

11407

GSK Investigational Site, Jerez de la Frontera

13005

GSK Investigational Site, Marseille

14642

GSK Investigational Site, Rochester

17019

GSK Investigational Site, La Rochelle

18017

GSK Investigational Site, Bethlehem

23235

GSK Investigational Site, Richmond

27599

GSK Investigational Site, Chapel Hill

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

31008

GSK Investigational Site, Pamplona

31059

GSK Investigational Site, Toulouse

32605

GSK Investigational Site, Gainesville

33321

GSK Investigational Site, Tamarac

33613

GSK Investigational Site, Tampa

34295

GSK Investigational Site, Montpellier

35043

GSK Investigational Site, Marburg

38043

GSK Investigational Site, Grenoble

40205

GSK Investigational Site, Louisville

40225

GSK Investigational Site, Düsseldorf

40509

GSK Investigational Site, Lexington

40549

GSK Investigational Site, Düsseldorf

41009

GSK Investigational Site, Seville

44093

GSK Investigational Site, Nantes

44137

GSK Investigational Site, Dortmund

45267

GSK Investigational Site, Cincinnati

47005

GSK Investigational Site, Valladolid

48149

GSK Investigational Site, Münster

50009

GSK Investigational Site, Zaragoza

53127

GSK Investigational Site, Bonn

59322

GSK Investigational Site, Valenciennes

60612

GSK Investigational Site, Chicago

63003

GSK Investigational Site, Clermont-Ferrand

65183

GSK Investigational Site, Wiesbaden

74137

GSK Investigational Site, Tulsa

80045

GSK Investigational Site, Aurora

81377

GSK Investigational Site, München

83642

GSK Investigational Site, Meridian

83706

GSK Investigational Site, Meridian

85704

GSK Investigational Site, Tucson

85925

GSK Investigational Site, La Roche-sur-Yon

90006

GSK Investigational Site, Los Angeles

90621

GSK Investigational Site, Buena Park

91942

GSK Investigational Site, San Diego

92592

GSK Investigational Site, Temecula

94010

GSK Investigational Site, Créteil

94304

GSK Investigational Site, Stanford

95300

GSK Investigational Site, Pontoise

100191

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

200065

GSK Investigational Site, Shanghai

264000

GSK Investigational Site, Yantai

266061

GSK Investigational Site, Qingdao

300201

GSK Investigational Site, Taiyuan

325000

GSK Investigational Site, Wenzhou

330006

GSK Investigational Site, Nanchang

430022

GSK Investigational Site, Wuhan

434020

GSK Investigational Site, Jingzhou

523326

GSK Investigational Site, Dongguan

02135

GSK Investigational Site, Boston

08901

GSK Investigational Site, New Brunswick

02914

GSK Investigational Site, Providence

75390-9035

GSK Investigational Site, Dallas

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

C1121ABE

GSK Investigational Site, Ciudad Autonoma de Bueno

B1602DOH

GSK Investigational Site, Florida

M5500CCG

GSK Investigational Site, Mendoza

S2000DBS

GSK Investigational Site, Rosario

L8L 2X2

GSK Investigational Site, Hamilton

N6A 4V2

GSK Investigational Site, London

K1H 1E4

GSK Investigational Site, Ottawa

H2V 2K1

GSK Investigational Site, Montreal

H2X 3E4

GSK Investigational Site, Montreal

G1S 4L8

GSK Investigational Site, Québec

G1V 4W2

GSK Investigational Site, Québec

01139

GSK Investigational Site, Dresden

01307

GSK Investigational Site, Dresden

790-0024

GSK Investigational Site, Ehime

798-8510

GSK Investigational Site, Ehime

910-1193

GSK Investigational Site, Fukui

806-8501

GSK Investigational Site, Fukuoka

920-0293

GSK Investigational Site, Ishikawa

231-8682

GSK Investigational Site, Kanagawa

250-8558

GSK Investigational Site, Kanagawa

860-0814

GSK Investigational Site, Kumamoto

600-8216

GSK Investigational Site, Kyoto

514-8507

GSK Investigational Site, Mie

392-8510

GSK Investigational Site, Nagano

560-0082

GSK Investigational Site, Osaka

570-8507

GSK Investigational Site, Osaka

160-0023

GSK Investigational Site, Tokyo

173-0026

GSK Investigational Site, Tokyo

1105 AZ

GSK Investigational Site, Amsterdam

2353 GA

GSK Investigational Site, Leiden

08022

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

NR31 6LA

GSK Investigational Site, Great Yarmouth

SG1 4AB

GSK Investigational Site, Stevenage

WN1 2NN

GSK Investigational Site, Wigan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05274750 - Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps | Biotech Hunter | Biotech Hunter